Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 7/2019

01-07-2019 | Original Article

Chemotherapy-induced fatigue is associated with changes in gene expression in the peripheral blood mononuclear cell fraction of patients with locoregional breast cancer

Authors: Barbara Bonaparte Ribas de Alcântara, Felipe Melo Cruz, Fernando Luiz Affonso Fonseca, Beatriz da Costa Aguiar Alves, Matheus Moreira Perez, Patricia Varela, João Bosco Pesquero, Daniel de Iracema Gomes Cubero, Claudia Vaz De Melo Sette, Auro Del Giglio

Published in: Supportive Care in Cancer | Issue 7/2019

Login to get access

Abstract

Purpose

Chemotherapy-induced fatigue (CIF) is a frequent symptom that impairs patient functioning and quality of life. We aimed to evaluate whether systemic chemotherapy can induce a specific gene expression profile in peripheral blood mononuclear cells (PBMNC) of patients with locoregional breast cancer (LRBC) who develop CIF.

Methods

PBMNC were collected from 3 patients who developed CIF before and after their initial cycle of chemotherapy, and RNA-seq was performed in an Ion Torrent™ System. A total of 12.345 transcripts were sequenced, of which 26 were selected out of 71 that had significantly different expression before and after chemotherapy. The RNA-seq results were validated by RT-qPCR in a different group of 28 patients with LRBC who developed CIF after their first cycle of chemotherapy and in six patients who also received chemotherapy but did not develop CIF (controls). We assessed CIF according the BFI and Chalder Questionnaires.

Results

We observed a significant increase in expression of DUSP18 and RHOBTB1 and decreased expression of NCAN and RAET1G in patients who developed CIF after chemotherapy. Control patients only exhibited a significant decrease in NCAN expression.

Conclusion

CIF induces specific changes in gene expression in the PBMNC of LRBC patients. Some of these changes, such as downregulation of NCAN expression, may reflect direct effects of chemotherapy since they are also observed in the controls. Furthermore, CIF may involve downregulation of skeletal muscle genes (RHOBT1, DUSP18) and immune systems (RAETG1), whereas NCAN downregulation may underlie the adverse cognitive effects of chemotherapy.
Appendix
Available only for authorised users
Literature
1.
Campos MP, Hassan BJ, Riechelmann R, Del Giglio A (2011) Cancer-related fatigue: a practical review. Ann Oncol 22:1273–1279CrossRefPubMed
2.
3.
Iop A, Manfredi AM, Bonura S (2004) Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol 15:712–720CrossRefPubMed
4.
Gilliam LA, St Clair DK (2011) Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal 15:254–2563CrossRef
5.
6.
Saligan LN, Olson K, Filler K, Larkin D, Cramp F, Sriram Y, Escalante CP, Del Giglio A, Kober KM, Kamath J, Palesh O, Mustian K, Multinational Association of Supportive Care in Cancer Fatigue Study Group – Biomarker Working Group (2015) The biology of cancer-related fatigue: a review of the literature. Support Care Cancer 23:2461–2478CrossRefPubMedPubMedCentral
7.
Halloran JW, Zhu D, Qian DC, Byun J, Gorlova OY, Amos CI, Gorlov IP (2015) Prediction of the gene expression in normal lung tissue by the gene expression in blood. BMC Med Genet 8:77
8.
Sullivan PF, Fan C, Perou CM (2006) Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141b:261–268CrossRefPubMed
9.
Glatt SJ, Everall IP, Kremen WS, Corbeil J, Šášik R, Khanlou N, Han M, Liew CC, Tsuang MT (2005) Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A 102:15533–15538CrossRefPubMedPubMedCentral
10.
Cruz FM, Munhoz BA, Alves BC, Gehrke FS, Fonseca FL, Kuniyoshi RK, Cubero D, Peppone LJ, Del Giglio A (2015) Biomarkers of fatigue related to adjuvant chemotherapy for breast cancer: evaluation of plasma and lymphocyte expression. Clin Transl Med 4:4CrossRefPubMedPubMedCentral
11.
Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186–1196CrossRefPubMed
12.
Jackson C (2015) The Chalder Fatigue Scale (CFQ 11). Occup Med 65(1):86–86CrossRef
13.
Barsevick A, Frost M, Zwinderman A, Hall P, Halyard M, GENEQOL Consortium (2010) I’m so tired: biological and genetic mechanisms of cancer related fatigue. Qual Life Res 19(10):1419–1427CrossRefPubMedPubMedCentral
14.
15.
16.
17.
Landmark-Høyvik H, Reinertsen KV, Loge JH, Kristensen VN, Dumeaux V, Fosså SD, Børresen-Dale AL, Edvardsen H (2010) The genetics and epigenetics of fatigue. PM R 2(5):456–465CrossRefPubMed
18.
Wang T, Yin J, Miller AH, Xiao C (2017) A systematic review of the association between fatigue and genetic polymorphisms. Brain Behav Immun 62:230–244CrossRefPubMedPubMedCentral
19.
Brown DJ, McMillan DC, Milroy R (2005) The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer 103:377–382CrossRefPubMed
20.
Wright MJ, Halton JM, Martin RF, Barr RD (1998) Long-term gross motor performance following treatment for acute lymphoblastic leukemia. Med Pediatr Oncol 31:86–90CrossRefPubMed
21.
Barreiro E, Hussain SN (2010) Protein carbonylation in skeletal muscles: impact on function. Antioxid Redox Signal 12:417–429CrossRefPubMed
22.
Kramer HF, Goodyear LJ (2007) Exercise, MAPK, and NF-κB signaling in skeletal muscle. J Appl Physiol (1985) 103:388–395CrossRef
23.
Widegren U, Ryder JW, Zierath JR (2001) Mitogen-activated protein kinase signal transduction in skeletal muscle: effects of exercise and muscle contraction. Acta Physiol Scand 172:227–238CrossRefPubMed
24.
25.
26.
Patterson KI, Brummer T, O'Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475–489CrossRefPubMed
27.
Mishra R, Polic B, Welsh RM, Szomolanyi-Tsuda E (2013) Inflammatory cytokine-mediated evasion of virus-induced tumors from NK cell control. J Immunol 191:961–970CrossRefPubMed
28.
Schultz CC, Mühleisen TW, Nenadic I, Koch K, Wagner G, Schachtzabel C, Siedek F, Nöthen MM, Rietschel M, Deufel T, Kiehntopf M, Cichon S, Reichenbach JR, Sauer H, Schlösser RG (2014) Common variation in NCAN, a risk factor for bipolar disorder and schizophrenia, influences local cortical folding in schizophrenia. Psychol Med 44(4):811–820CrossRefPubMed
29.
Einarsdottir E, Peyrard-Janvid M, Darki F, Tuulari JJ, Merisaari H, Karlsson L, Scheinin NM, Saunavaara J, Parkkola R, Kantojärvi K, Ämmälä AJ, Yu NYL, Matsson H, Nopola-Hemmi J, Karlsson H, Paunio T, Klingberg T, Leinonen E, Kere J (2017) Identification of NCAN as a candidate gene for developmental dyslexia. Sci Rep 7:9294CrossRefPubMedPubMedCentral
30.
Wang P, Cai J, Ni J, Zhang J, Tang W, Zhang C (2016) The NCAN gene: schizophrenia susceptibility and cognitive dysfunction. Neuropsychiatr Dis Treat 12:2875–2883CrossRefPubMedPubMedCentral
31.
Wang XM, Walitt B, Saligan L, Tiwari AF, Cheung CW, Zhang ZJ (2015) Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine 72:86–96CrossRefPubMedPubMedCentral
32.
Flowers E, Miaskowski C, Conley Y, Hammer MJ, Levine J, Mastick J, Paul S, Wright F, Kober K (2018) Differential expression of genes and differentially pertubed pathways associated with very high evening fatigue in oncology patients receiving chemotherapy. Support Care Cancer 26:739–750CrossRefPubMed
33.
Bower JE, Ganz PA, Irwin MR, Arevalo JMG, Cole SW (2011) Fatigue and gene expression in human leukocytes: increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav Immun 25:147–150CrossRefPubMed
34.
Landmark-Høyvik H, Reinertsen KV, Loge JH, Fosså SD, Børresen-Dale AL, Dumeaux V (2009) Alterations of gene expression in blood cells associated with chronic fatigue in breast cancer survivors. Pharmacogenomics J 9:333–340CrossRefPubMed
35.
Saligan LN, Hsiao CP, Wang D, Wang XM, St John L, Kaushal A, Citrin D, Barb JJ, Munson PJ, Dionne RA (2013) Upregulation of α-synuclein during localized radiation therapy signals the association of cancer-related fatigue with the activation of inflammatory and neuroprotective pathways. Brain Behav Immun 27:63–70CrossRefPubMed
36.
Kober KM, Dunn L, Mastick J, Cooper B, Langford D, Melisko M, Venook A, Chen LM, Wright F, Hammer M, Schmidt BL, Levine J, Miaskowski C, Aouizerat BE (2016) Gene expression profiling of evening fatigue in women undergoing chemotherapy for breast cancer. Biol Res Nurs 18:370–385CrossRefPubMedPubMedCentral
37.
Hsiao CP, Reddy SY, Chen MK, Saligan LN (2016) Genomic profile of fatigued men receiving localized radiation therapy. Biol Res Nurs 18:281–289CrossRefPubMed
Metadata
Title
Chemotherapy-induced fatigue is associated with changes in gene expression in the peripheral blood mononuclear cell fraction of patients with locoregional breast cancer
Authors
Barbara Bonaparte Ribas de Alcântara
Felipe Melo Cruz
Fernando Luiz Affonso Fonseca
Beatriz da Costa Aguiar Alves
Matheus Moreira Perez
Patricia Varela
João Bosco Pesquero
Daniel de Iracema Gomes Cubero
Claudia Vaz De Melo Sette
Auro Del Giglio
Publication date
01-07-2019
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 7/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4519-0

Other articles of this Issue 7/2019

Supportive Care in Cancer 7/2019 Go to the issue

Commentary

Social support buffers against anxiety and depressive symptoms in patients with cancer only if support is wanted: a large sample replication

Original Article

Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study

Original Article

Documentation and incidence of late effects and screening recommendations for adolescent and young adult head and neck cancer survivors treated with radiotherapy

Original Article

Parental psychological distress and cancer stage: a comparison of adults with metastatic and non-metastatic cancer

Original Article

Association of emergency department admission and early inpatient palliative care consultation with hospital mortality in a comprehensive cancer center

Original Article

Clinical significance of weight changes at diagnosis in solid tumours
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits